What happened with ABT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Medical devices are Abbott Laboratories’ largest business. It sells products that help treat heart conditions, continuously monitor glucose and manage chronic pain or movement disorders. Hospitals, physicians’ offices and consumers buy these products directly or through distributors. Abbott also sells diagnostic systems and tests to hospitals, laboratories and other testing sites.
Its other businesses supply nutrition products for children and adults, sold to consumers and through retailers and healthcare institutions, and branded generic medicines sold in emerging markets outside the United States. Most of Abbott’s sales come from outside the United States, but it does not depend on any single customer whose loss would materially harm the company.
Selling these products depends on regulatory permission to market them and continued compliance with manufacturing, testing, labeling and other requirements. Regulators can restrict approved uses, suspend sales or stop production when products or facilities fail to comply.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Abbott’s results hinge on Libre adoption, cardiovascular procedures, nutrition and diagnostic testing, but important rivals Roche and Siemens Healthineers are missing from this list.
Dexcom competes directly with Abbott’s Libre to supply people with diabetes with sensors that continuously track glucose. Watch Dexcom’s sensor sales alongside Abbott’s CGM revenue, which reached $7.6 billion in 2025 and grew 17.4% excluding currency effects.
Medtronic competes with Abbott to supply healthcare providers with heart valves, devices that manage heart rhythm or support failing hearts, and devices that stimulate nerves. Its product launches in these areas are worth watching for competition facing Abbott’s device business.
Boston Scientific competes with Abbott for healthcare providers’ purchases of devices used to diagnose and treat heart-rhythm problems, treat blood vessels and stimulate nerves. Watch its cardiovascular devices rather than its broader medical-device sales when comparing competition with Abbott.
Edwards Lifesciences competes with Abbott to supply heart-valve treatments, including valves delivered through a catheter rather than open-heart surgery, surgical valves, and catheter-based mitral and tricuspid therapies. Its mitral and tricuspid therapy sales are especially useful to watch: Edwards names Abbott as its primary competitor there.
Johnson & Johnson’s Biosense Webster competes with Abbott to supply hospitals with systems that map the heart’s electrical activity and treat abnormal rhythms through cardiac ablation. Its news in these systems is the relevant comparison for Abbott, rather than Johnson & Johnson’s prescription-medicine business.
QuidelOrtho competes with Abbott for hospitals, laboratories and blood banks buying laboratory, transfusion, point-of-care and molecular tests. Watch its recurring sales of tests, reagents and supplies tied to installed instruments for a view of ongoing testing demand.
Bio-Rad competes with Abbott for laboratories buying diagnostic testing products. Focus on its Clinical Diagnostics sales, which made up about 60% of its 2025 revenue, rather than its separate life-science research business.
MiniMed both competes with Abbott through its own glucose sensors and pays Abbott per sensor for products integrated into certain insulin-delivery systems under a long-term supply agreement. Watch adoption of those systems by people needing intensive insulin therapy, since they provide an outlet for Abbott sensors alongside MiniMed’s own.
BD competes with Abbott to sell diagnostic products to clinical laboratories and cardiac-intervention devices to healthcare institutions, but its planned diagnostics separation reduces that overlap. Watch the separation of its Diagnostic Solutions business to understand how much diagnostic competition remains within BD.
Integer depends on Abbott’s manufacturing orders: it makes medical-device components and systems for Abbott, which accounted for more than 10% of Integer’s sales in 2025. Its cardiovascular and implantable-device manufacturing sales offer a view of demand from device makers, though they are not Abbott-only revenue.
Insulet’s Omnipod 5 insulin-delivery system can support demand for Abbott sensors because it uses compatible Libre glucose readings to adjust insulin doses for people with insulin-dependent diabetes. Watch adoption of Libre-compatible Omnipod 5 systems, rather than all Omnipod sales, because the system also integrates other suppliers’ sensors.
Dr. Reddy’s competes with Abbott’s Indian pharmaceutical operations in branded medicines for patients; Abbott sells its branded generics through buyers including wholesalers, pharmacies and healthcare facilities. Watch Dr. Reddy’s branded-medicine business in India rather than its worldwide generics sales when assessing this competition.
Abbott Laboratories earningsThis company
Abbott’s report will show whether medical-device growth can keep offsetting pressure in diagnostics and nutrition and translate into profit.
Read segment sales alongside the gross profit margin. Check whether medical devices, especially Diabetes Care, keep growing and whether sales in Diagnostics or Nutrition stabilize. Device growth with a recovery in either pressured segment and a steady margin would show that growth is broadening and converting into profit. Slower device growth, continued weakness in Diagnostics or Nutrition, or a margin squeezed by costs would show that growth remains concentrated and profit is under pressure.
Integer Holdings Corporation earningsITGR
Integer Holdings Corporation makes components and systems for device makers including Abbott, so its report offers a signal on demand behind Abbott’s device business, though not an Abbott-only measure.
Watch sales from Integer’s cardiovascular and implantable-device manufacturing; they come from multiple device makers and are not a direct measure of Abbott’s orders. Stronger sales would suggest firmer demand across this part of the device supply chain, a supportive backdrop for Abbott’s device business. Weaker sales would flag possible softness, but Integer’s results alone cannot establish how Abbott’s orders changed.
Dr. Reddy's Laboratories Limited earningsRDY
Dr. Reddy’s sells branded medicines in India in competition with Abbott’s local pharmaceutical business, and its branded-medicine sales will show how that contest is developing.
Focus on Dr. Reddy’s branded-medicine business in India, not its worldwide generics sales. Stronger branded-medicine sales would show a competitor growing in a market Abbott serves, potentially intensifying the contest for patients and buyers. Weaker sales would mean a softer competitive signal, but would not prove that Abbott gained share.
Boston Scientific Corp. earningsBSX
Boston Scientific also sells rhythm, vascular and nerve-stimulation devices to healthcare providers, so its results in these areas show the competitive backdrop for Abbott.
Watch Boston Scientific’s cardiovascular-device business, especially areas that overlap with Abbott’s rhythm-management, vascular and nerve-stimulation products. Stronger sales in those areas would point to solid demand for competing products and a tougher contest for provider purchases; weaker sales would signal less momentum from this rival, but would not establish a change in Abbott’s sales.
Fed Interest Rate Decision
Fed rate decisions shape the cost of borrowing, which can raise or lower Abbott’s interest expense on its $12.9 billion of debt and financing for its planned acquisition.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can make new borrowing for the acquisition more expensive and increase costs on debt that reprices, leaving less cash from operations for Abbott’s products, facilities and other needs.
If it comes in below expectations
Lower rates can make new acquisition borrowing cheaper and reduce costs on debt that reprices, leaving Abbott with more cash from operations for its products, facilities and other needs.
DexCom, Inc. earningsDXCM
Dexcom competes with Abbott’s Libre for continuous glucose-monitoring users, and its sensor sales provide a read on competitive momentum alongside Abbott’s $7.6 billion CGM business in 2025.
Compare the growth in Dexcom’s sensor sales with the context that Abbott’s CGM sales grew 17.4% in 2025 excluding foreign exchange. Faster growth at Dexcom would signal stronger momentum from Abbott’s direct rival and greater competitive pressure on Abbott’s sensor business; slower growth would mean less relative momentum. The companies’ sales can differ by product mix, geography and pricing, so the comparison does not establish Abbott’s market share.
Edwards Lifesciences Corp earningsEW
Edwards Lifesciences competes directly with Abbott in mitral and tricuspid therapies, and its sales in those treatments will show the competitive momentum facing Abbott’s structural-heart business.
Focus on Edwards’ mitral and tricuspid therapy sales, not just its company-wide results. These treatments compete directly with Abbott’s structural-heart products. Stronger sales would show Edwards gaining momentum in this part of the market and a tougher contest for provider purchases; weaker sales would mean less momentum from this rival, not a conclusion about Abbott’s entire device business.
QuidelOrtho Corporation earningsQDEL
QuidelOrtho competes with Abbott for testing purchases by hospitals, laboratories and blood banks, and its instrument-linked sales of tests and supplies show ongoing testing demand.
Watch sales of tests, reagents and supplies used with installed instruments; these show whether hospitals and laboratories continue to use their testing systems. Stronger sales would suggest sustained testing demand and a steadier market backdrop for Abbott’s diagnostics. Weaker sales would point to softer ongoing purchases. The companies’ products and customers do not match exactly, so QuidelOrtho’s results are not a substitute for Abbott’s sales.
MiniMed Group, Inc. earningsMMEDV
Some MiniMed Group insulin-delivery systems use Abbott sensors, so adoption of those systems can show demand through this sales channel, even as MiniMed also sells its own sensors.
Focus on adoption of the insulin-delivery systems that use Abbott sensors, not MiniMed’s total system sales. Greater adoption can support Abbott sensor supply and sales, adding a source of demand for Abbott’s CGM business; weaker adoption would mean less support from this channel. Because MiniMed also sells its own sensors, the effect depends on which sensors users choose.
